Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Placebo-Controlled, Sequential Single Dose Escalation Study of the Safety, Pharmacokinetics, and Antiretroviral Activity of IVTMB-365 in HIV-1 Infected Participants

Next Previous
Trial Profile

A Phase Placebo-Controlled, Sequential Single Dose Escalation Study of the Safety, Pharmacokinetics, and Antiretroviral Activity of IVTMB-365 in HIV-1 Infected Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TMB 365 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors TaiMed Biologics

Most Recent Events

  • 05 Oct 2021 Status changed from recruiting to completed.
  • 01 Oct 2021 According to a TaiMed Biologics media release, the company has submitted the study results to the FDA, and requested a pre-IND meeting for a phase 2a study of a combination of TMB-365 and TMB-380.
  • 01 Oct 2021 Results presented in a TaiMed Biologics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top